muscle diseases

#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy
Endpoints
Thu, 01/14/21 - 10:34 am
Avidity
JPMHC 2021
oligonucleotide-based therapies
muscle diseases
Dyne starts life with $50M, big biopharma names for muscle disease work
Fierce Biotech
Wed, 04/3/19 - 09:39 pm
Dyne
muscle diseases
Atlas Venture